Nexalin Technology Inc（NXL）财务数据NXLNexalin Technology Inc

Nexalin Technology Inc (NXL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Equipment , accounting for 74.4% of total sales, equivalent to $52.53K. Other significant revenue streams include Licensing Fee and Other. Understanding this composition is critical for investors evaluating how NXL navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Nexalin Technology Inc maintains a gross margin of 73.16%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -18479.69%, while the net margin is -18412.71%. These profitability ratios, combined with a Return on Equity (ROE) of -240.25%, provide a clear picture of how effectively NXL converts its operational activities into shareholder value.

In the context of the broader market, NXL competes directly with industry leaders such as TRIB and VNRX. With a market capitalization of $6.54M, it holds a significant position in the sector. When comparing efficiency, NXL's gross margin of 73.16% stands against TRIB's 35.21% and VNRX's 100.00%. Such benchmarking helps identify whether Nexalin Technology Inc is trading at a premium or discount relative to its financial performance.

Nexalin has shown inconsistent revenue growth, with total revenue of 12,161 USD in Q2 2026, down from 171,895 USD in Q4 2025. The gross margin remains relatively high at 73.16%, but the net income continues to be negative, highlighting ongoing financial struggles.